Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort
CONCLUSIONS: In summary, eculizumab is the treatment of choice for cTMA patients that do not respond to plasma therapy. In patients with sTMA and C3G, the response rates to therapy are much lower and therefore, the decision to start therapy needs to be considered carefully.PMID:33599971 | DOI:10.1007/s40620-021-00981-8
Source: Journal of Nephrology - Category: Urology & Nephrology Authors: Christof Aigner Martina Gaggl Gunar Stemer Michael Eder Georg B öhmig Renate Kain Zolt án Prohászka N óra Garam Dorottya Csuka Raute Sunder-Plassmann Leah Charlotte Piggott Natalja Haninger-Vacariu Alice Schmidt Gere Sunder-Plassmann Source Type: research